Think IPO. Think IPOX®.
Specialized solutions for investors seeking exposure to the companies shaping what comes next.
IPOX® International Index
Tracked byFirst Trust International Equity Opportunities ETF FPXI ETF ↗
Upcoming listings
Anthropic
AI software
Big Caring Group
Pharmacy retail
Blue Lagoon
Geothermal spas and hotels
HiJoJo Partners
Startup investing
METKA
Infrastructure construction
Japan Home Shield
Geotechnical and inspection services
Adel
Neurodegenerative medicines
NOTA
Accommodation and development
SmartNews
Mobile applications
WHI Holdings
Enterprise HR software
FOLIO Holdings
Financial technology
IG Holdings
IT hardware sales
INTERX
Manufacturing AI
13 upcoming listings
News
Reuters: IPOX® Associate Lukas Muehlbauer Comments on Investor Demand for Anthropic’s Record IPO
Reuters cited IPOX® Associate Lukas Muehlbauer ahead of Anthropic’s Nasdaq debut after the Claude maker raised a record $81 billion, pricing 980 million shares at $83, above its $70–$78 range, for a $1.5 trillion valuation. Muehlbauer noted that some of the demand may reflect investors not wanting to miss a rare chance to gain exposure to a leading AI company, even as its long-term profitability remains uncertain.
Reuters: IPOX® Associate Lukas Muehlbauer Comments on a Record but Selective U.S. IPO Market
Reuters cited IPOX® Associate Lukas Muehlbauer on a U.S. IPO market that has set fundraising records in 2026 while listing counts stay well below historical highs. Anthropic’s $81.3 billion IPO and SpaceX’s $75 billion offering carried proceeds past the 2021 record. Muehlbauer noted that the two deals will account for about two-thirds of the year’s proceeds and described 2026 as a selective reopening, with many companies now looking to 2027.
Bloomberg: IPOX® Associate Lukas Muehlbauer Comments on Airtel Money’s London Aftermarket Rebound
Bloomberg cited IPOX® Associate Lukas Muehlbauer on the recovery of African mobile money and payments provider Airtel Money after a shaky London debut. The shares closed at 226p on November 18, about 15% above the 196p IPO price, after trading more than 10% below it in the first week. Muehlbauer said investors appear increasingly confident in the company’s growth story, and that disciplined pricing in a buyer’s market left room for aftermarket gains, a good sign for London’s IPO pipeline.
Money Life with Chuck Jaffe: IPOX® CEO Josef Schuster Discusses Anthropic’s IPO
IPOX® CEO Josef Schuster joined Chuck Jaffe on the Money Life podcast on November 18 to discuss Anthropic’s upcoming IPO, the first large pure-play AI listing. Schuster compared the deal with SpaceX, expects the stock to be volatile until earnings provide a fundamental anchor, and explained why IPOX® treats IPOs as a separate equity sector for their first four years of trading. His segment starts at 7:00; the full transcript is included.
Reuters: IPOX® Associate Lukas Muehlbauer Discusses Anthropic’s IPO Valuation and AI Economics
Reuters featured IPOX® Associate Lukas Muehlbauer in coverage of Anthropic’s IPO roadshow and potential valuation of up to $1.4 trillion. Muehlbauer discussed the lack of direct listed peers and the importance of cash generation after model-development and computing costs, customer retention, and improving inference economics.
Bloomberg: IPOX® Associate Lukas Muehlbauer Comments on Saudi Arabia’s IPO Rule Changes
IPOX® Associate Lukas Muehlbauer discussed Saudi Arabia’s new IPO regulations in Bloomberg, highlighting how earlier underwriting commitments could increase risks for banks and encourage more selective dealmaking. While the reforms may temporarily slow issuance, stronger scrutiny of valuations could benefit investors. Muehlbauer emphasized that a healthy IPO market depends not on the number of listings, but on attractive aftermarket performance that sustains long-term investor confidence and encourages future market participation.
A world of new listings.
A disciplined approach.
New listings reflect economic growth and innovation. Our services bring a disciplined approach to this evolving global universe through independent research, index licensing, portfolio management and tailored investment solutions.
Explore our services